Related Experiment Videos
Clinical trial with cyclosporin A
A Cimitan1, F Fantini, A Giannetti
1Department of Dermatology, University of Modena, Italy.
Acta Dermato-Venereologica. Supplementum
|January 1, 1989
Summary
Low-dose Cyclosporin A (CsA) effectively treated severe psoriasis in most male patients, achieving near-complete remission. Relapse occurred upon treatment cessation, indicating CsA
Area of Science:
- Dermatology
- Immunosuppressive Therapy
Background:
- Psoriasis is a chronic autoimmune skin condition.
- Conventional treatments often fail for extensive or severe psoriasis.
Observation:
- Six male patients with severe, treatment-resistant psoriasis were enrolled.
- Patients had generalized pustular psoriasis, psoriatic erythroderma, or chronic plaque psoriasis.
Findings:
- Oral low-dose Cyclosporin A (5 mg/kg/day) was administered.
- Near-complete remission was achieved in 4 out of 6 patients.
- One patient experienced incomplete response; another discontinued due to infections.
Implications:
- Low-dose Cyclosporin A shows significant efficacy for severe psoriasis.
- Treatment cessation leads to relapse, suggesting long-term management is necessary.
- Monitoring for infections is crucial during Cyclosporin A therapy.